Bristol Myers Squibb stock heads into the open after a 3.2 percent drop

Bristol Myers Squibb stock closed at USD 64.69 on the NYSE on September 9, 2026, down 3.19 percent from the previous session based on NYSE data cited by MarketWatch. The move came as the shares traded between USD 64.40 and USD 65.89 during the day, within a 52-week range of USD 42.52 to USD 68.64.

September 9, 2026 in numbers

Bristol Myers Squibb Co. (ISIN US0897961004, NYSE: BMY) ended the last completed New York session at USD 64.69 on September 9, 2026, a decline of 3.19 percent versus its prior close, according to quote data from MarketWatch. Intraday, the stock traded in a range from a low of USD 64.40 to a high of USD 65.89 on the NYSE, with the closing level sitting closer to the lower end of that band. Per the same MarketWatch overview, the shares remained within a documented 52-week span between USD 42.52 on the downside and USD 68.64 on the upside, underscoring that the latest pullback still leaves the stock closer to the upper half of its one-year corridor than the bottom.

While Bristol Myers Squibb lagged in the most recent session, broader equities also faced pressure as major United States benchmarks lost ground on September 9, 2026. As Yahoo Finance reported for that trading day, the Dow Jones Industrial Average fell 1.2 percent to 52,786.07, signaling that Bristol Myers Squibb shares underperformed an already weak blue-chip index when they dropped 3.19 percent in the same session. Sector commentary around large-cap pharmaceuticals focused more on valuation and pipeline positioning than on a single headline, with Zacks highlighting on September 9, 2026 that Bristol Myers trades at a discount to the broader large-cap pharma group while working to expand its portfolio.

Today's context for Bristol Myers Squibb stock

Heading into today's United States session on September 10, 2026, Bristol Myers Squibb stock carries the prior close of USD 64.69 on the NYSE as the reference point, with traders watching whether broader risk sentiment and sector flows extend or reverse the previous day's weakness. United States equity futures and energy markets shaped the backdrop late in the prior cycle, as Reuters noted on September 9, 2026 that Wall Street futures were muted while Brent crude oil prices moved above USD 100 per barrel ahead of key inflation data. That combination of cautious index positioning and higher energy costs may influence sentiment toward large-cap pharmaceutical names like Bristol Myers Squibb today, even in the absence of a specific company event dated September 10, 2026 in the available calendars.